111 Capital Invests $148,000 in Novavax, Inc. $NVAX

111 Capital bought a new position in Novavax, Inc. (NASDAQ:NVAX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,533 shares of the biopharmaceutical company’s stock, valued at approximately $148,000.

Several other hedge funds have also recently modified their holdings of the stock. Signaturefd LLC lifted its holdings in shares of Novavax by 47.2% in the second quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,122 shares in the last quarter. Kapitalo Investimentos Ltda purchased a new position in shares of Novavax in the second quarter worth $79,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Novavax in the second quarter worth $1,016,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Novavax in the second quarter worth $73,000. Finally, Rhumbline Advisers raised its stake in Novavax by 3.3% during the first quarter. Rhumbline Advisers now owns 215,413 shares of the biopharmaceutical company’s stock valued at $1,381,000 after purchasing an additional 6,949 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Price Performance

NVAX stock opened at $9.22 on Wednesday. Novavax, Inc. has a 12 month low of $5.01 and a 12 month high of $13.61. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The company has a 50-day moving average price of $8.22 and a 200 day moving average price of $7.26. The stock has a market cap of $1.50 billion, a PE ratio of 4.04, a P/E/G ratio of 0.12 and a beta of 2.74.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The firm had revenue of $239.24 million during the quarter, compared to analysts’ expectations of $149.19 million. During the same period in the previous year, the company earned $0.99 EPS. The firm’s revenue for the quarter was down 42.4% compared to the same quarter last year. Equities research analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analyst Ratings Changes

NVAX has been the topic of a number of recent research reports. Citigroup initiated coverage on shares of Novavax in a research note on Tuesday, June 17th. They set a “sell” rating and a $6.00 price target on the stock. Bank of America reaffirmed an “underperform” rating and set a $7.00 price target (down previously from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. HC Wainwright initiated coverage on shares of Novavax in a research note on Thursday, August 28th. They set a “buy” rating and a $10.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novavax in a research note on Saturday, September 27th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $14.29.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.